{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-036988","form_type":"8-K","ticker":"AMLX","cik":"0001658551","company_name":"Amylyx Pharmaceuticals, Inc.","filed_at":"2023-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.037236+00:00","generated_at":"2026-06-19T14:01:42.751318+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Amylyx expects Q4 and FY 2022 revenue to meaningfully exceed consensus on higher RELYVRIO demand","bullets":["Insurers covering ~25% of U.S. covered lives have published policies; nearly all provide broad access to RELYVRIO.","EU decision on AMX0035 marketing authorization for ALS expected first half 2023; CHMP SAG meeting this month.","Phase 3 PHOENIX trial (664 participants) completed enrollment; topline results anticipated mid-2024.","Starting Feb 19, pharmacy network data will no longer flow to third-party data vendors (closed network model).","Company provides update at SVB Securities conference; Q4 and FY 2022 financial results call in early March 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-036988","json":"https://secwatch.observer/filing/0001193125-23-036988.json","markdown":"https://secwatch.observer/filing/0001193125-23-036988.md","text":"https://secwatch.observer/filing/0001193125-23-036988.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658551/000119312523036988/0001193125-23-036988-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658551/000119312523036988/d461886d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T14:01:42.751318+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}